Sarepta Therapeutics (SRPT) 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	SRPT
Entity Registrant Name	Sarepta Therapeutics, Inc.
Entity Central Index Key	873303
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		41,466,092

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$74,436	$73,551
Short-term investments	91,787	136,793
Accounts receivable	2,416	2,416
Other current assets	24,410	35,036
Total Current Assets	193,049	247,796
Restricted cash and investments	783	782
Property and equipment, net of accumulated depreciation and amortization of $21,037 and $19,896 as of March 31, 2015 and December 31, 2014, respectively	37,759	38,501
Patent costs, net of accumulated amortization of $2,216 and $2,081 as of March 31, 2015 and December 31, 2014, respectively	5,842	5,891
Other assets	5,275	2,063
Total Assets	242,708	295,033
Current Liabilities:
Accounts payable	9,318	12,408
Accrued expenses	15,039	17,366
Current portion of long-term debt	99	98
Current portion of notes payable	4,831	2,492
Deferred revenue	3,363	3,318
Other liabilities	1,256	1,185
Total Current Liabilities	33,906	36,867
Long-term debt	1,450	1,476
Notes payable		2,262
Deferred rent	6,593	6,775
Total Liabilities	41,949	47,380
Commitments and contingencies (Note 9)
Stockholders' Equity:
Preferred stock, $.0001 par value, 3,333,333 shares authorized; none issued and outstanding
Common stock, $.0001 par value, 50,000,000 shares authorized; 41,354,142 and 41,311,512 issued and outstanding at March 31, 2015 and December 31, 2014, respectively	4	4
Additional paid-in capital	941,356	926,769
Accumulated other comprehensive loss	-17	-95
Accumulated deficit	-740,584	-679,025
Total Stockholders' Equity	200,759	247,653
Total Liabilities and Stockholders' Equity	$242,708	$295,033

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Property and equipment, accumulated depreciation and amortization	$21,037	$19,896
Patent costs, accumulated amortization	$2,216	$2,081
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	3,333,333	3,333,333
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, issued	41,354,142	41,311,512
Common stock, outstanding	41,354,142	41,311,512

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue from research contracts and other grants		$6,088
Operating expenses:
Research and development	39,165	20,906
General and administrative	22,697	10,303
Total operating expenses	61,862	31,209
Operating loss	-61,862	-25,121
Other income (loss):
Interest income and other, net	303	99
Loss on change in warrant valuation		-3,251
Total other income (loss)	303	-3,152
Net loss	-61,559	-28,273
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	78	-59
Total other comprehensive gain (loss)	78	-59
Comprehensive loss	($61,481)	($28,332)
Net loss per share:
Net loss per share - basic and diluted	($1.49)	($0.75)
Weighted average number of common shares outstanding for computing basic and diluted net loss per share	41,324	37,821

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($61,559)	($28,273)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	1,280	523
Amortization of premium on available-for-sale securities and other non-cash interest expense	315	519
Loss on abandonment of patents and disposal of property and equipment	131	6
Stock-based compensation	14,156	4,342
Increase in warrant valuation		3,251
Changes in operating assets and liabilities, net:
Net increase in accounts receivable		-4,319
Net decrease (increase) in other assets	7,413	-6,018
Net (decrease) increase in accounts payable, accrued expenses, deferred revenue and other liabilities	-5,084	1,704
Net cash used in operating activities	-43,348	-28,265
Cash flows from investing activities:
Purchase of property and equipment	-532	-5,326
Patent costs	-391	-294
Purchase of available-for-sale securities		-176,669
Sale of available-for-sale securities	44,750
Net cash provided by (used in) investing activities	43,827	-182,289
Cash flows from financing activities:
Proceeds from exercise of options and warrants	431	2,713
Repayments of long-term debt	-25	-23
Net cash provided by financing activities	406	2,690
Increase (decrease) in cash and cash equivalents	885	-207,864
Cash and cash equivalents:
Beginning of period	73,551	256,965
End of period	74,436	49,101
Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	18	20
Supplemental Schedule of Noncash Investing Activities and Financing Activities:
Issuance of common stock in satisfaction of warrants and other liabilities		3,044
Capitalized interest	99
Tenant improvements paid by landlord		593
Property and equipment included in accrued expenses	45	3,533
Patent costs included in accrued expenses	$100	$200

BUSINESS_AND_BASIS_OF_PRESENTA

BUSINESS AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
BUSINESS AND BASIS OF PRESENTATION	1. BUSINESS AND BASIS OF PRESENTATION
	Business
	Sarepta Therapeutics, Inc. (together with its wholly-owned subsidiaries “Sarepta” or the “Company”) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. Applying its proprietary, highly-differentiated and innovative platform technologies, the Company is able to target a broad range of diseases and disorders through distinct RNA-targeted mechanisms of action. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (“DMD”) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Company is also developing therapeutics using its technology for the treatment of drug resistant bacteria and infectious, rare and other human diseases.
	The Company has not generated any revenue from product sales to date and there can be no assurance that revenue from product sales will be achieved. Even if it does achieve revenue from product sales, the Company is likely to continue to incur operating losses in the near term.
	As of March 31, 2015, the Company had approximately $167.0 million of cash, cash equivalents and investments, consisting of $74.4 million of cash and cash equivalents, $91.8 million of short-term investments and $0.8 million of restricted cash and investments. The Company believes that its balance of cash, cash equivalents and investments is sufficient to fund its current operational plan for the next twelve months, though it may pursue additional cash resources through public or private financings, seek additional government contracts and establish collaborations with or license its technology to other companies.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), reflect the accounts of Sarepta Therapeutics, Inc. and its wholly-owned subsidiaries. All inter-company transactions between and among its consolidated subsidiaries have been eliminated. Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	Estimates and Uncertainties
	The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of stock-based awards, research and development expenses, revenue recognition and income tax.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	2. RECENT ACCOUNTING PRONOUNCEMENTS
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15 which requires an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will not be able to meet its obligations as they become due within one year after the date that the financial statements are issued or available to be issued. If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management’s plans to mitigate those relevant conditions or events, the entity is required to disclose (1) principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, (2) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, and (3) management’s plans that alleviate substantial doubt about the entity’s ability to continue as a going concern. However, if conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, and substantial doubt is not alleviated after consideration of management’s plans, an entity should include a statement in a footnote indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. ASU No. 2014-15 is effective for the annual period ending after December 15, 2016, with early adoption permitted. The Company has not adopted this guidance as of March 31, 2015, and based on the Company’s financial condition as of March 31, 2015, the Company does not expect the adoption of this guidance to have any impact on the current period financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Under the new guidance, a company is required to recognize revenue when it transfers goods or renders services to customers at an amount that it expects to be entitled to in exchange for these goods or services. This guidance is effective for fiscal years beginning after December 15, 2016, with early adoption not permitted. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	3. FAIR VALUE MEASUREMENTS
	The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
		•		Level 1 — quoted prices for identical instruments in active markets;
		•		Level 2 — quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and
		•		Level 3 — valuations derived from valuation techniques in which one or more significant value drivers are unobservable.
	The tables below present information about the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques it utilizes to determine such fair value:
			Fair Value Measurement as of March 31, 2015
			Total		Level 1		Level 2		Level 3
			(in thousands)
	Money market funds		$	363	$	363	$	—	$	—
	Commercial paper			37,398		—		37,398		—
	Government and government agency bonds			77,229		—		77,229		—
	Corporate bonds			30,059		—		30,059		—
	Certificates of deposit			648		648		—		—
	Total assets		$	145,697	$	1,011	$	144,686	$	—
			Fair Value Measurement as of December 31, 2014
			Total		Level 1		Level 2		Level 3
			(in thousands)
	Money market funds		$	47,740	$	47,740	$	—	$	—
	Commercial paper			2,997		—		2,997		—
	Government and government agency bonds			75,250		—		75,250		—
	Corporate bonds			58,546		—		58,546		—
	Certificates of deposit			647		647		—		—
	Total assets		$	185,180	$	48,387	$	136,793	$	—

CASH_CASH_EQUIVALENTS_AND_SHOR

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	4. CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
	It is the Company’s policy to mitigate credit risk in its financial assets by maintaining a well-diversified portfolio that limits the amount of exposure as to maturity and investment type. The average maturity of the Company’s available-for-sale securities as of March 31, 2015 and December 31, 2014 was less than 12 months.
	The following tables summarize the Company’s cash, cash equivalents and short-term investments for each of the periods indicated:
		As of March 31, 2015
		Amortized		Gross		Gross			Fair
		Cost		Unrealized		Unrealized			Market
				Gains		Losses			Value
		(in thousands)
	Cash and money market funds	$	21,537	$	—	$	—		$	21,537
	Commercial paper		37,399		—		(1	)		37,398
	Government and government agency bonds		77,232		—		(3	)		77,229
	Corporate bonds		30,072		—		(13	)		30,059
	Total	$	166,240	$	—	$	(17	)	$	166,223
	As reported:
	Cash and cash equivalents		74,436		—		—			74,436
	Short-term investments		91,804		—		(17	)		91,787
	Total	$	166,240	$	—	$	(17	)	$	166,223
		As of December 31, 2014
		Amortized		Gross		Gross			Fair
		Cost		Unrealized		Unrealized			Market
				Gains		Losses			Value
		(in thousands)
	Cash and money market funds	$	73,551	$	—	$	—		$	73,551
	Commercial paper		2,997		—		—			2,997
	Government and government agency bonds		75,289		—		(39	)		75,250
	Corporate bonds		58,602		—		(56	)		58,546
	Total	$	210,439	$	—	$	(95	)	$	210,344
	As reported:
	Cash and cash equivalents		73,551		—		—			73,551
	Short-term investments		136,888		—		(95	)		136,793
	Total	$	210,439	$	—	$	(95	)	$	210,344

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER CURRENT ASSETS	5. OTHER CURRENT ASSETS
	The following table summarizes the Company’s other current assets for each of the periods indicated:
		As of		As of
		March 31,		December 31,
		2015		2014
		(in thousands)
	Manufacturing-related deposits	$	20,658	$	30,668
	Prepaid expenses		3,309		2,797
	Other current assets		443		1,571
	Total	$	24,410	$	35,036

ACCRUED_EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	6. ACCRUED EXPENSES
	The following table summarizes the Company’s accrued expenses for each of the periods indicated:
		As of		As of
		March 31,		December 31,
		2015		2014
		(in thousands)
	Accrued contract manufacturing costs	$	4,006	$	3,271
	Accrued contract research costs		4,553		3,782
	Accrued employee compensation costs		3,022		6,170
	Accrued professional fees		2,541		3,403
	Accrued facility-related costs		224		300
	Other accrued expenses		693		440
	Total	$	15,039	$	17,366

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	7. STOCK-BASED COMPENSATION
	The following table summarizes the Company’s stock awards granted for each of the periods indicated:
			For the Three Months Ended March 31,
			2015					2014
			Grants		Weighted			Grants		Weighted
					Average					Average
					Grant Date					Grant Date
					Fair Value					Fair Value
	Stock options*			1,607,544	$	10.35			1,185,265	$	19.41
	Restricted stock awards			6,000	$	13.9			6,000	$	29.03
	*	Stock options granted for both periods presented in the table have only service-based criteria and vest over four years.
	Stock-based Compensation Expense
	For the three months ended March 31, 2015 and 2014, total stock-based compensation expense was $14.2 million and $4.3 million, respectively. Included in this amount for the three months ended March 31, 2015 is $8.7 million of stock-based compensation expense incurred in connection with the resignation of the Company’s former Chief Executive Officer (“CEO”). The following table summarizes share-based compensation expense by function included within the unaudited condensed consolidated statements of operations and comprehensive loss:
			For the Three Months Ended
			March 31,
			2015		2014
			(in thousands)
	Research and development		$	2,446	$	1,873
	General and administrative			11,710		2,469
	Total		$	14,156	$	4,342
	The following table summarizes share-based compensation expense by grant type included within the unaudited condensed consolidated statements of operations and comprehensive loss:
			For the Three Months Ended
			March 31,
			2015		2014
			(in thousands)
	Stock options		$	13,551	$	3,911
	Restricted stock awards			42		64
	Restricted stock units			—		(4	)
	Stock appreciation rights			147		147
	Employee stock purchase plan			416		224
	Total		$	14,156	$	4,342

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
NET LOSS PER SHARE	8. NET LOSS PER SHARE
	Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding. Given that the Company is in a loss position for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be anti-dilutive and, therefore, they are excluded from the diluted net loss per share calculation.
			For the Three Months Ended
			March 31,
			2015			2014
			(in thousands, except per
			share amounts)
	Net loss		$	(61,559	)	$	(28,273	)
	Weighted-average number of shares of common stock and common stock equivalents outstanding:
	Weighted-average number of shares of common stock outstanding for computing basic earnings per share			41,324			37,821
	Dilutive effect of outstanding warrants and stock options after application of the treasury stock method*			—			—
	Weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for computing diluted earnings per share			41,324			37,821
	Net loss per share — basic and diluted		$	(1.49	)	$	(0.75	)
	*	For the three months ended March 31, 2015, stock options, restricted stock awards and stock appreciation rights to purchase 6,938,993 shares of common stock were excluded from the net loss per share calculation as their effect would have been anti-dilutive.
	For the three months ended March 31, 2014, warrants, stock options, restricted stock awards, restricted stock units and stock appreciation rights to purchase 6,096,000 shares of common stock were excluded from the net loss per share calculation as their effect would have been anti-dilutive.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES
	Purchase Commitments
	The following table presents non-cancelable contractual obligations arising from arrangements that the Company has entered into from time to time for the provision of goods and services:
		As of
		March 31, 2015
		(in thousands)
	2015 (9 months)	$	40,833
	2016		40,188
	2017		23,940
	2018		14,260
	2019		5,703
	Total	$	124,924
	Litigation
	In the normal course of business, the Company may from time to time be named as a party to various legal claims, actions and complaints, including matters involving securities, employment, intellectual property, effects from the use of therapeutics utilizing its technology, or others. For example, purported class action complaints were filed against the Company and certain of its officers in the U.S. District Court for the District of Massachusetts on January 27, 2014 and January 29, 2014. The complaints were consolidated into a single action (Corban v. Sarepta, et. al., No. 14-cv-10201) by order of the court on June 23, 2014, and plaintiffs were afforded 28 days to file a consolidated amended complaint. The plaintiffs’ consolidated amended complaint, filed on July 21, 2014, sought to bring claims on behalf of themselves and persons or entities that purchased or acquired securities of the Company between July 10, 2013 and November 11, 2013. The consolidated amended complaint alleged that Sarepta and certain of its officers violated the federal securities laws in connection with disclosures related to eteplirsen, the Company’s lead therapeutic candidate for DMD, and seeks damages in an unspecified amount. Pursuant to the court’s June 23, 2014 order, Sarepta filed a motion to dismiss the consolidated amended complaint on August 18, 2014, and argument on the motion was held on March 12, 2015. On March 31, 2015, the Court dismissed plaintiffs’ amended complaint. Plaintiffs in the Corban suit have filed an amended complaint and the Company plans to file a response by the deadline provided by the court in May 2015.
	Another complaint was filed in the U.S. District Court for the District of Massachusetts on December 3, 2014 by William Kader, Individually and on Behalf of All Others Similarly Situated v. Sarepta Therapeutics Inc., Christopher Garabedian, and Sandesh Mahatme (Kader v. Sarepta et.al 1:14-cv-14318), asserting violations of Section 10(b) of the Exchange Act and Securities and Exchange Commission Rule 10b-5 against the Company, Christopher Garabedian and Sandesh Mahatme. Plaintiffs’ amended complaint, filed on March 20, 2015, alleges that the defendants made material misrepresentations or omissions during the putative class period of April 21, 2014 through October 27, 2014, regarding the sufficiency of the Company’s data for submission of an new drug application for eteplirsen and the likelihood of the Food and Drug Administration accepting a new drug application based on that data. Plaintiff seeks compensatory damages and fees. The Company received service of the complaint on January 5, 2015. Sarepta filed a motion to dismiss the complaint on May 4, 2015, pursuant to the scheduling order entered on February 20, 2015.
	In addition, two derivative suits were filed based upon the Company’s disclosures related to eteplirsen. On February 5, 2015, a derivative suit was filed against the Company’s Board of Directors in the 215th Judicial District of Harris County, Texas (David Smith, derivatively on behalf of Sarepta Therapeutics, Inc., v. Christopher Garabedian et. al, Cause No. 2015-06645). The claims allege that Sarepta’s directors caused Sarepta to disseminate materially false and/or misleading statements in connection with disclosures concerning the Company’s submission of a new drug application for eteplirsen. Plaintiff seeks unspecified compensatory damages, actions to reform and improve corporate governance and internal procedures, disgorgement of profits, benefits and other compensation obtained by the directors, and attorneys’ fees. On March 26, 2015, the parties agreed to abate the case pending the resolution of both suits pending in federal court in the District of Massachusetts, Corban and Kader. Additionally, on February 24, 2015, a derivative suit was filed against the Company’s Board of Directors with the Court of Chancery of the State of Delaware (Ira Gaines, and the Ira J. Gaines Revocable Trust U/A, on behalf of nominal defendant Sarepta Therapeutics, Inc., vs. Goolsbee et. al., No. 10713). The claims allege that the defendants participated in making material misrepresentations or omissions during the period of April 21, 2014 through October 27, 2014, regarding the sufficiency of the Company’s data for submission of a new drug application for eteplirsen and the likelihood of the Food and Drug Administration accepting a new drug application based on that data. Plaintiffs seek unspecified compensatory damages, punitive damages, actions to reform and improve corporate governance and internal procedures, and attorneys’ fees. On March 26, 2015, the parties agreed to stay the case pending the resolution of Kader, pending in federal court in the District of Massachusetts.
	Additionally, on September 23, 2014, a derivative suit was filed against the Company’s Board of Directors with the Court of Chancery of the State of Delaware (Terry McDonald, derivatively on behalf of Sarepta Therapeutics, Inc., et. al vs. Goolsbee et. al., No. 10157). The claims allege, among other things, that (i) the Company’s non-employee directors paid themselves excessive compensation fees for 2013, (ii) that the compensation for the Company’s former Chief Executive Officer (“CEO”), Christopher Garabedian, was also excessive and such fees were the basis for Mr. Garabedian not objecting to or stopping the excessive fees for the non-employee directors and (iii) that the disclosure in the 2013 proxy statement was deficient. The relief sought, among others, includes disgorgement and rescindment of excessive or unfair payments and equity grants to Mr. Garabedian and the directors, unspecified damages plus interest, a class action declaration for the suit declaring approval of the Company’s Amended and Restated 2011 Equity Plan at the 2013 annual meeting ineffective and a revote for approved amendments, correction of misleading disclosures and plaintiff’s attorney fees. Given the relatively early stage of the proceedings in the Kader suit, at this time, no assessment can be made as to the likely outcome of the claims or whether the outcome would have a material impact on the Company. We have reached an agreement in principle with the parties in the McDonald suit and do not believe that disposition of the McDonald suit should have a material financial impact on the Company.

BUSINESS_AND_BASIS_OF_PRESENTA1

BUSINESS AND BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), reflect the accounts of Sarepta Therapeutics, Inc. and its wholly-owned subsidiaries. All inter-company transactions between and among its consolidated subsidiaries have been eliminated. Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
Estimates and Uncertainties	Estimates and Uncertainties
	The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of stock-based awards, research and development expenses, revenue recognition and income tax.
Recent Accounting Pronouncements	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15 which requires an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will not be able to meet its obligations as they become due within one year after the date that the financial statements are issued or available to be issued. If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management’s plans to mitigate those relevant conditions or events, the entity is required to disclose (1) principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, (2) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, and (3) management’s plans that alleviate substantial doubt about the entity’s ability to continue as a going concern. However, if conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, and substantial doubt is not alleviated after consideration of management’s plans, an entity should include a statement in a footnote indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. ASU No. 2014-15 is effective for the annual period ending after December 15, 2016, with early adoption permitted. The Company has not adopted this guidance as of March 31, 2015, and based on the Company’s financial condition as of March 31, 2015, the Company does not expect the adoption of this guidance to have any impact on the current period financial statements.”
	In May 2014, the FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Under the new guidance, a company is required to recognize revenue when it transfers goods or renders services to customers at an amount that it expects to be entitled to in exchange for these goods or services. This guidance is effective for fiscal years beginning after December 15, 2016, with early adoption not permitted. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured and Carried at Fair Value	The tables below present information about the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques it utilizes to determine such fair value:
		Fair Value Measurement as of March 31, 2015
		Total		Level 1		Level 2		Level 3
		(in thousands)
	Money market funds	$	363	$	363	$	—	$	—
	Commercial paper		37,398		—		37,398		—
	Government and government agency bonds		77,229		—		77,229		—
	Corporate bonds		30,059		—		30,059		—
	Certificates of deposit		648		648		—		—
	Total assets	$	145,697	$	1,011	$	144,686	$	—
		Fair Value Measurement as of December 31, 2014
		Total		Level 1		Level 2		Level 3
		(in thousands)
	Money market funds	$	47,740	$	47,740	$	—	$	—
	Commercial paper		2,997		—		2,997		—
	Government and government agency bonds		75,250		—		75,250		—
	Corporate bonds		58,546		—		58,546		—
	Certificates of deposit		647		647		—		—
	Total assets	$	185,180	$	48,387	$	136,793	$	—

CASH_CASH_EQUIVALENTS_AND_SHOR1

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Summary of Company Cash, Cash Equivalents and Short-Term Investments	The following tables summarize the Company’s cash, cash equivalents and short-term investments for each of the periods indicated:
		As of March 31, 2015
		Amortized		Gross		Gross			Fair
		Cost		Unrealized		Unrealized			Market
				Gains		Losses			Value
		(in thousands)
	Cash and money market funds	$	21,537	$	—	$	—		$	21,537
	Commercial paper		37,399		—		(1	)		37,398
	Government and government agency bonds		77,232		—		(3	)		77,229
	Corporate bonds		30,072		—		(13	)		30,059
	Total	$	166,240	$	—	$	(17	)	$	166,223
	As reported:
	Cash and cash equivalents		74,436		—		—			74,436
	Short-term investments		91,804		—		(17	)		91,787
	Total	$	166,240	$	—	$	(17	)	$	166,223
		As of December 31, 2014
		Amortized		Gross		Gross			Fair
		Cost		Unrealized		Unrealized			Market
				Gains		Losses			Value
		(in thousands)
	Cash and money market funds	$	73,551	$	—	$	—		$	73,551
	Commercial paper		2,997		—		—			2,997
	Government and government agency bonds		75,289		—		(39	)		75,250
	Corporate bonds		58,602		—		(56	)		58,546
	Total	$	210,439	$	—	$	(95	)	$	210,344
	As reported:
	Cash and cash equivalents		73,551		—		—			73,551
	Short-term investments		136,888		—		(95	)		136,793
	Total	$	210,439	$	—	$	(95	)	$	210,344

OTHER_CURRENT_ASSETS_Tables

OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Summary of Other Current Assets	The following table summarizes the Company’s other current assets for each of the periods indicated:
		As of		As of
		March 31,		December 31,
		2015		2014
		(in thousands)
	Manufacturing-related deposits	$	20,658	$	30,668
	Prepaid expenses		3,309		2,797
	Other current assets		443		1,571
	Total	$	24,410	$	35,036

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Summary of Accrued Expenses	The following table summarizes the Company’s accrued expenses for each of the periods indicated:
		As of		As of
		March 31,		December 31,
		2015		2014
		(in thousands)
	Accrued contract manufacturing costs	$	4,006	$	3,271
	Accrued contract research costs		4,553		3,782
	Accrued employee compensation costs		3,022		6,170
	Accrued professional fees		2,541		3,403
	Accrued facility-related costs		224		300
	Other accrued expenses		693		440
	Total	$	15,039	$	17,366

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Awards Granted	The following table summarizes the Company’s stock awards granted for each of the periods indicated:
			For the Three Months Ended March 31,
			2015					2014
			Grants		Weighted			Grants		Weighted
					Average					Average
					Grant Date					Grant Date
					Fair Value					Fair Value
	Stock options*			1,607,544	$	10.35			1,185,265	$	19.41
	Restricted stock awards			6,000	$	13.9			6,000	$	29.03
	*	Stock options granted for both periods presented in the table have only service-based criteria and vest over four years.
Summary of Stock-Based Compensation Expense by Function Included within Condensed Consolidated Statement of Operations and Comprehensive Loss	The following table summarizes share-based compensation expense by function included within the unaudited condensed consolidated statements of operations and comprehensive loss:
			For the Three Months Ended
			March 31,
			2015		2014
			(in thousands)
	Research and development		$	2,446	$	1,873
	General and administrative			11,710		2,469
	Total		$	14,156	$	4,342
Summary of Stock-Based Compensation Expense by Grant Type Included within Condensed Consolidated Statement of Operations and Comprehensive Loss	The following table summarizes share-based compensation expense by grant type included within the unaudited condensed consolidated statements of operations and comprehensive loss:
			For the Three Months Ended
			March 31,
			2015		2014
			(in thousands)
	Stock options		$	13,551	$	3,911
	Restricted stock awards			42		64
	Restricted stock units			—		(4	)
	Stock appreciation rights			147		147
	Employee stock purchase plan			416		224
	Total		$	14,156	$	4,342

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share
			For the Three Months Ended
			March 31,
			2015			2014
			(in thousands, except per
			share amounts)
	Net loss		$	(61,559	)	$	(28,273	)
	Weighted-average number of shares of common stock and common stock equivalents outstanding:
	Weighted-average number of shares of common stock outstanding for computing basic earnings per share			41,324			37,821
	Dilutive effect of outstanding warrants and stock options after application of the treasury stock method*			—			—
	Weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for computing diluted earnings per share			41,324			37,821
	Net loss per share — basic and diluted		$	(1.49	)	$	(0.75	)
	*	For the three months ended March 31, 2015, stock options, restricted stock awards and stock appreciation rights to purchase 6,938,993 shares of common stock were excluded from the net loss per share calculation as their effect would have been anti-dilutive.
	For the three months ended March 31, 2014, warrants, stock options, restricted stock awards, restricted stock units and stock appreciation rights to purchase 6,096,000 shares of common stock were excluded from the net loss per share calculation as their effect would have been anti-dilutive.

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Non-Cancelable Contractual Obligations	The following table presents non-cancelable contractual obligations arising from arrangements that the Company has entered into from time to time for the provision of goods and services:
		As of
		March 31, 2015
		(in thousands)
	2015 (9 months)	$	40,833
	2016		40,188
	2017		23,940
	2018		14,260
	2019		5,703
	Total	$	124,924

Recovered_Sheet1

Business and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
	Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents and investments	$167,000,000
Cash and cash equivalents	74,436,000	73,551,000	49,101,000	256,965,000
Short-term investments	91,787,000	136,793,000
Restricted cash and investments	$783,000	$782,000
Number of operating segments	1

Assets_and_Liabilities_Measure

Assets and Liabilities Measured and Carried at Fair Value (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$145,697	$185,180
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	363	47,740
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	37,398	2,997
Government and Government Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	77,229	75,250
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	30,059	58,546
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	648	647
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	1,011	48,387
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	363	47,740
Level 1 [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	648	647
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	144,686	136,793
Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	37,398	2,997
Level 2 [Member] | Government and Government Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	77,229	75,250
Level 2 [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$30,059	$58,546

Summary_of_Company_Cash_Cash_E

Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost	$166,240	$210,439
Cash, cash equivalents and short-term investments, Gross unrealized gains	0	0
Cash, cash equivalents and short-term investments, Gross unrealized losses	-17	-95
Cash, cash equivalents and short-term investments, Fair market value	166,223	210,344
Cash and Cash Equivalents [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost	74,436	73,551
Cash, cash equivalents and short-term investments, Gross unrealized gains	0	0
Cash, cash equivalents and short-term investments, Fair market value	74,436	73,551
Short-term Investments [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost	91,804	136,888
Cash, cash equivalents and short-term investments, Gross unrealized gains	0	0
Cash, cash equivalents and short-term investments, Gross unrealized losses	-17	-95
Cash, cash equivalents and short-term investments, Fair market value	91,787	136,793
Cash and Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost	21,537	73,551
Cash, cash equivalents and short-term investments, Gross unrealized gains	0	0
Cash, cash equivalents and short-term investments, Fair market value	21,537	73,551
Commercial Paper [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost	37,399	2,997
Cash, cash equivalents and short-term investments, Gross unrealized gains	0	0
Cash, cash equivalents and short-term investments, Gross unrealized losses	-1
Cash, cash equivalents and short-term investments, Fair market value	37,398	2,997
US Government Debt Securities [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost	77,232	75,289
Cash, cash equivalents and short-term investments, Gross unrealized gains	0	0
Cash, cash equivalents and short-term investments, Gross unrealized losses	-3	-39
Cash, cash equivalents and short-term investments, Fair market value	77,229	75,250
Corporate Bonds [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost	30,072	58,602
Cash, cash equivalents and short-term investments, Gross unrealized gains	0	0
Cash, cash equivalents and short-term investments, Gross unrealized losses	-13	-56
Cash, cash equivalents and short-term investments, Fair market value	$30,059	$58,546

Summary_of_Other_Current_Asset

Summary of Other Current Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Prepaid Expense and Other Assets, Current [Abstract]
Manufacturing-related deposits	$20,658	$30,668
Prepaid expenses	3,309	2,797
Other current assets	443	1,571
Total	$24,410	$35,036

Summary_of_Accrued_Expenses_De

Summary of Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued contract manufacturing costs	$4,006	$3,271
Accrued contract research costs	4,553	3,782
Accrued employee compensation costs	3,022	6,170
Accrued professional fees	2,541	3,403
Accrued facility-related costs	224	300
Other accrued expenses	693	440
Total	$15,039	$17,366

Summary_of_Stock_Awards_Grante

Summary of Stock Awards Granted (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants, Stock options	1,607,544	[1]	1,185,265	[1]
Weighted Average Grant Date Fair Value, Stock options	$10.35	[1]	$19.41	[1]
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants, Restricted stock awards	6,000		6,000
Weighted Average Grant Date Fair Value, Restricted stock awards	$13.90		$29.03
[1]	Stock options granted for both periods presented in the table have only service-based criteria and vest over four years.

Summary_of_Stock_Awards_Grante1

Summary of Stock Awards Granted (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share based compensation granted under plan vest period	4 years	4 years

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$14,156	$4,342
Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$8,700

Summary_of_StockBased_Compensa

Summary of Stock-Based Compensation Expense by Function Included within Condensed Consolidated Statement of Operations and Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$14,156	$4,342
Research and Development Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	2,446	1,873
General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$11,710	$2,469

Summary_of_StockBased_Compensa1

Summary of Stock-Based Compensation Expense by Grant Type Included within Condensed Consolidated Statement of Operations and Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$14,156	$4,342
Stock Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	13,551	3,911
Restricted Stock Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	42	64
Restricted Stock Units (RSUs) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense		-4
Stock Appreciation Rights [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	147	147
Employee Stock Purchase Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$416	$224

Basic_and_Diluted_Net_Loss_Per

Basic and Diluted Net Loss Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
Earnings Per Share [Abstract]
Net loss	($61,559)		($28,273)
Weighted-average number of shares of common stock and common stock equivalents outstanding:
Weighted-average number of shares of common stock outstanding for computing basic earnings per share	41,324		37,821
Dilutive effect of outstanding warrants and stock options after application of the treasury stock method	0	[1]	0	[2]
Weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for computing diluted earnings per share	41,324		37,821
Net loss per share - basic and diluted	($1.49)		($0.75)
[1]	For the three months ended March 31, 2015, stock options, restricted stock awards and stock appreciation rights to purchase 6,938,993 shares of common stock were excluded from the net loss per share calculation as their effect would have been anti-dilutive.
[2]	For the three months ended March 31, 2014, warrants, stock options, restricted stock awards, restricted stock units and stock appreciation rights to purchase 6,096,000 shares of common stock were excluded from the net loss per share calculation as their effect would have been anti-dilutive.

Basic_and_Diluted_Net_Loss_Per1

Basic and Diluted Net Loss Per Share (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from computation of earning per share	6,938,993	6,096,000

NonCancelable_Contractual_Obli

Non-Cancelable Contractual Obligations (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
2015 (9 months)	$40,833
2016	40,188
2017	23,940
2018	14,260
2019	5,703
Total	$124,924

Recovered_Sheet2

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Law affected under lawsuit filling	The consolidated amended complaint alleged that Sarepta and certain of its officers violated the federal securities laws in connection with disclosures related to eteplirsen
Number of days to amend plaintiffs complaint	28 days